Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?

Current Opinion in Hematology
Roland B Walter

Abstract

Therapeutic failure in acute myeloid leukemia remains common. It may be advantageous to identify patients with suboptimal treatment responses early as they may benefit from timely care strategy changes. Here, responses portending failure of standard induction therapy are reviewed and therapeutic options examined, including use of investigational, targeted agents for suitable patients. Patients entering complete remission without minimal residual disease early, that is, with one cycle of standard induction chemotherapy, have a lower relapse risk and live longer than other similarly-treated patients, supporting the proposition of early complete remission without minimal residual disease as a criterion for induction therapy success. Investigational small molecule drugs are appealing for patients who fail standard therapies, but complete remission rates as a single agent are typically modest. The relative value of different treatment strategies if a first standard induction therapy cycle fails to produce complete remission is unknown. However, retreatment with the same therapy often leads to complete remission and provides a benchmark against which other approaches should be compared. Addition of investigational small molecule drug...Continue Reading

References

Dec 1, 1961·Journal of Chronic Diseases·E J FREIREICHE FREI
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Nov 11, 2006·Blood·Frederick R AppelbaumMartin S Tallman
Feb 6, 2008·American Journal of Hematology·Kebede HusseinDaniel Weisdorf
Nov 26, 2010·The New England Journal of Medicine·Ted A GooleyGeorge B McDonald
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hiroto InabaDario Campana
Feb 13, 2013·Lancet·Felicetto Ferrara, Charles A Schiffer
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Jun 27, 2013·Nature Reviews. Clinical Oncology·Christopher S Hourigan, Judith E Karp
Jul 12, 2013·The New England Journal of Medicine·Francesco Lo-CocoUNKNOWN Study Alliance Leukemia
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettDonald Milligan
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesMark Levis
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monique TerwijnGerrit J Schuurhuis
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvie D FreemanAlan K Burnett
Mar 4, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marina Y KonoplevaHagop M Kantarjian
Aug 1, 2014·The Lancet Oncology·Sara C Meyer, Ross L Levine
Dec 3, 2014·Leukemia Research·Sylvain ThepotUNKNOWN Groupe Francophone des Myelodysplasies (GFM)
Jan 30, 2015·Blood·Sabine KayserRoland B Walter
Mar 4, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xueyan ChenElihu H Estey
Jun 27, 2015·Seminars in Hematology·Peter HoklandChristopher S Hourigan

❮ Previous
Next ❯

Citations

Apr 7, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland B Walter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Therapeutic Advances in Hematology
James K Mangan, Selina M Luger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Dimitri A BreemsBob Löwenberg
© 2022 Meta ULC. All rights reserved